Loading the comparison…
Loading the comparison…
Any covered state and procedure, side by side
| Tumor & fibroid embolization · South Dakota | Tumor & fibroid embolization · Illinois | |
|---|---|---|
| Surgeons, 2024 | 2 | 14 |
| Medicare fee-for-service cases | 101 | 674 |
| Growth since 2019 (Medicare FFS) | +20%/yr | +3.6%/yr |
| Forecast cases (Medicare FFS) | 180 in 2030 | 1,750 in 2030 |
| Forecast growth | +9.6%/yr to 2030 | +17%/yr to 2030 |
| Per 1,000 Medicare beneficiaries | 0.8 | 0.5 |
| Medicare Advantage share | 39% | 47% |
| Out of hospital | 42% | 49% (+49 pts since 2019) |
| Cases per surgeon | 51 | 48 |
| Top 10 surgeons' share | 100% | 83% |
| Surgeons growing | 0 | 0 |
| New since the base year | 2 | 3 |
| Likely to stop billing it | 0 by 2026 | 1 by 2026 |
| Forecast miss, 1 year (procedure) | 11% | 11% |
| Company payments per surgeon | $7,210 | $119K |
The counts above are the surgeons MedaRep names: who is growing, who is new, who is likely to stop and which companies engage them.